Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Keyphrases

• Denosumab 100%
• Skeletal-related Events 100%
• Multiple Myeloma 20%
• Solid Tumors 20%
• Bone Metastasis 20%
• Phase 3 Trial 20%
• Zoledronate 20%
• Patient Management 10%
• Risk Reduction 10%
• Antitumor Therapy 10%
• Tumor Subtype 10%
• Clinical Experience 10%
• Bisphosphonates 10%
• Clinical Management 10%
• Clinical Utility 10%
• Median Time 10%
• Economic Burden 10%
• Hypocalcemia 10%
• Antiresorptive 10%
• Newly Diagnosed multiple Myeloma 10%
• Receptor Activator of nuclear factor-B Ligand 10%
• Dosing Schedule 10%
• Osteonecrosis of the Jaw 10%
• Treatment Burden 10%
• Subcutaneous Administration 10%
• Strong Opioids 10%
• Treatment Discontinuation 10%
• Multiple Patients 10%
• Pain Outcomes 10%
• Atypical Femur Fracture 10%
• RANKL Inhibitor 10%
• Fracture Events 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Denosumab 100%
• Multiple Myeloma 30%
• Bone Metastasis 20%
• Solid Malignant Neoplasm 20%
• Zoledronic Acid 20%
• Receptor 10%
• Osteoclast Differentiation Factor 10%
• Bisphosphonic Acid Derivative 10%
• Subcutaneous Injection 10%
• Spine Fracture 10%
• Alternative Complement Pathway C3 C5 Convertase 10%
• Nuclear Factor 10%
• Jaw Osteonecrosis 10%
• Hypocalcaemia 10%
• Femur Fracture 10%